FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281981569> ?p ?o ?g. }

• W4281981569 endingPage "e20016" @default.
• W4281981569 startingPage "e20016" @default.
• W4281981569 abstract "e20016 Background: K is a 2nd-generation proteasome inhibitor (PI) approved for the treatment of multiple myeloma (MM). K-based regimens are associated with higher rates of CV toxicity compared with other PIs. We conducted a retrospective analysis to assess incidence of CV adverse events (AE) and outcomes of MM patients (pts) treated with K using a step-up TD schedule compared to SD protocol. Methods: A retrospective chart review was performed of MM pts treated with K at The Ohio State University Comprehensive Cancer Center (OSUCCC) from 1/1/13 to 9/1/19. Pt demographics, disease and K-related characteristics, CV AE, and follow-up information were collected. Pts were excluded if treated at both local center and at OSUCCC, not K-naïve when receiving treatment at OSUCCC, received a single dose of K while inpatient with no intent to continue treatment outpatient, or had a treatment plan entered but never received it. Results: Of the 166 pt charts analyzed, 36 were treated using a TD method (ex. step-wise C1D1 20mg/m 2 , C1D8 27mg/m 2 , C1D15 36mg/m 2 , for goal C2D1 56mg/m 2 onwards) and 130 pts were treated using a standard dosing method (ex. C1D1 20mg/m 2 and C1D8 56mg/m 2 onwards). Pre-existing CV risk factors were similar between the two groups. There was a slight difference in baseline renal function (TD: median CrCl 94mL/min, SD: 76mL/min; p=0.01) and prior PI use (TD: 86.1%, SD: 95%; p=0.048) between the two groups. In pts treated with TD, hypertension (HTN) developed earlier compared with SD (p=0.02). There was a lower incidence of onset of dyspnea in the TD group compared to SD group (16.7% vs 36.2%, respectively; p=0.03). There were no differences in incidence of HTN, congestive heart failure, ischemic heart disease, arrythmias, or pulmonary HTN. The median number of cycles administered to titrated pts was 7 (range: 2-56) compared to 3 (range: 1-44) for standard pts (p<0.001). There was no statistical difference in CV AE being the cause for treatment discontinuation between the two groups. The overall response rate (ORR) was higher in the TD group compared to the SD group (63.9% vs 42.8%, respectively; p=0.04). Five-year overall survival (OS) was improved in patients treated with TD than with SD (43.8% vs 17.5%, respectively; p<0.001). By multivariable analysis, TD was associated with improved OS compared to SD (HR 0.47; 95% CI 0.29-0.77-3.58; P=0.003). Conclusions: A simple modification of K titration dosing improved the tolerability of MM therapy without compromising efficacy. Although there were no differences in AE being the cause of treatment discontinuation between the two groups, an improvement in duration of therapy, ORR, and OS was observed in the TD group. As a result, TD is the standard-of-care dosing for MM pts treated with K at the OSUCCC. Prospective trials are needed to confirm the safety and efficacy of this dosing regimen." @default.
• W4281981569 created "2022-06-13" @default.
• W4281981569 creator A5006976206 @default.
• W4281981569 creator A5010473913 @default.
• W4281981569 creator A5014248827 @default.
• W4281981569 creator A5019488668 @default.
• W4281981569 creator A5026731813 @default.
• W4281981569 creator A5034020009 @default.
• W4281981569 creator A5038026501 @default.
• W4281981569 creator A5056645750 @default.
• W4281981569 creator A5073720570 @default.
• W4281981569 creator A5078508615 @default.
• W4281981569 date "2022-06-01" @default.
• W4281981569 modified "2023-09-27" @default.
• W4281981569 title "Step-up titration dosing (TD) of carfilzomib (K) is associated with prolonged duration of therapy and improved treatment outcomes compared to standard dosing (SD) in patients with multiple myeloma (MM)." @default.
• W4281981569 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e20016" @default.
• W4281981569 hasPublicationYear "2022" @default.
• W4281981569 type Work @default.
• W4281981569 citedByCount "0" @default.
• W4281981569 crossrefType "journal-article" @default.
• W4281981569 hasAuthorship W4281981569A5006976206 @default.
• W4281981569 hasAuthorship W4281981569A5010473913 @default.
• W4281981569 hasAuthorship W4281981569A5014248827 @default.
• W4281981569 hasAuthorship W4281981569A5019488668 @default.
• W4281981569 hasAuthorship W4281981569A5026731813 @default.
• W4281981569 hasAuthorship W4281981569A5034020009 @default.
• W4281981569 hasAuthorship W4281981569A5038026501 @default.
• W4281981569 hasAuthorship W4281981569A5056645750 @default.
• W4281981569 hasAuthorship W4281981569A5073720570 @default.
• W4281981569 hasAuthorship W4281981569A5078508615 @default.
• W4281981569 hasConcept C126322002 @default.
• W4281981569 hasConcept C126894567 @default.
• W4281981569 hasConcept C141071460 @default.
• W4281981569 hasConcept C159641895 @default.
• W4281981569 hasConcept C167135981 @default.
• W4281981569 hasConcept C197934379 @default.
• W4281981569 hasConcept C2776364478 @default.
• W4281981569 hasConcept C2777288759 @default.
• W4281981569 hasConcept C2778367456 @default.
• W4281981569 hasConcept C2780108899 @default.
• W4281981569 hasConcept C71924100 @default.
• W4281981569 hasConceptScore W4281981569C126322002 @default.
• W4281981569 hasConceptScore W4281981569C126894567 @default.
• W4281981569 hasConceptScore W4281981569C141071460 @default.
• W4281981569 hasConceptScore W4281981569C159641895 @default.
• W4281981569 hasConceptScore W4281981569C167135981 @default.
• W4281981569 hasConceptScore W4281981569C197934379 @default.
• W4281981569 hasConceptScore W4281981569C2776364478 @default.
• W4281981569 hasConceptScore W4281981569C2777288759 @default.
• W4281981569 hasConceptScore W4281981569C2778367456 @default.
• W4281981569 hasConceptScore W4281981569C2780108899 @default.
• W4281981569 hasConceptScore W4281981569C71924100 @default.
• W4281981569 hasIssue "16_suppl" @default.
• W4281981569 hasLocation W42819815691 @default.
• W4281981569 hasOpenAccess W4281981569 @default.
• W4281981569 hasPrimaryLocation W42819815691 @default.
• W4281981569 hasRelatedWork W1995894256 @default.
• W4281981569 hasRelatedWork W2084265116 @default.
• W4281981569 hasRelatedWork W2096413704 @default.
• W4281981569 hasRelatedWork W2102088366 @default.
• W4281981569 hasRelatedWork W2400769328 @default.
• W4281981569 hasRelatedWork W2896370738 @default.
• W4281981569 hasRelatedWork W3013147311 @default.
• W4281981569 hasRelatedWork W3162193073 @default.
• W4281981569 hasRelatedWork W4228998320 @default.
• W4281981569 hasRelatedWork W4287190190 @default.
• W4281981569 hasVolume "40" @default.
• W4281981569 isParatext "false" @default.
• W4281981569 isRetracted "false" @default.
• W4281981569 workType "article" @default.